BLA 125151 · Shire
Elaprase
Idursulfase · Iv (Infusion) · Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 16, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jul 24, 2006
Approved uses
3
Original approval plus efficacy supplements
Registered trials
20
9 Phase 3, 1 recruiting
FAERS reports
3,986
3,520 serious, 684 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF ANAPHYLAXIS Life-threatening anaphylactic reactions have occurred in some patients during and up to 24 hours after ELAPRASE infusions. Anaphylaxis, presenting as respiratory distress, hypoxia, hypotension, urticaria and/or angioedema of throat or tongue have been reported to occur during and after ELAPRASE infusions, regardless of duration of the course of treatment. Closely observe patients during and after ELAPRASE administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions and require additional monitoring [see Warnings and Precautions (5.1 , 5.3) and Adverse Reactions...
What it is approved for
From the label in effect Apr 15, 2025.
ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4) ]. ELAPRASE is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age ( 1 ).
Mechanism: Hunter syndrome (Mucopolysaccharidosis II, MPS II) is an X-linked recessive disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. This enzyme cleaves the terminal 2- O -sulfate moieties from the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate. Due to the missing or defective iduronate-2-sulfatase enzyme in patients with Hunter syndrome, GAG progressively accumulate in the lysosomes of a variety of cells, leading to cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. ELAPRASE is intended to provide exogenous enzyme...
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 24, 2013 Supplement 184 · Efficacy · priority review OrphanLabelLetter
- Jun 24, 2013 Supplement 152 · Efficacy LabelLetter
- Jul 24, 2006 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLetter
1 products under this application
- ELAPRASE · IDURSULFASE 6MG/3ML · INJECTABLE, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Idursulfase" as an intervention, any sponsor and status, largest first.
- Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00069641 · 96 participants · Start Sep 18, 2003 · Primary completion Mar 16, 2005
Drug: Iduronate-2-sulfatase enzyme replacement therapy; iduronate-2-sulfatase enzyme replacement therapy and 1 more · For: Mucopolysaccharidosis II
Sites: Oakland, California; St Louis, Missouri; Chapel Hill, North Carolina · 9 sites in all
- Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving IdursulfasePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00630747 · 94 participants · Start Sep 13, 2004 · Primary completion Jan 31, 2008
Drug: Idursulfase · For: Hunter Syndrome; Mucopolysaccharidosis II (MPS II)
Sites: Phoenix, Arizona; Oakland, California; Denver, Colorado · 52 sites in all
- A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)Pivotal-lookingActive, not recruiting
JCR Pharmaceuticals Co., Ltd.Industry
NCT04573023 · 86 participants · Start Feb 14, 2022 · Primary completion Oct 31, 2027
Drug: JR-141; Idursulfase and 1 more · For: Mucopolysaccharidosis II
Sites: Phoenix, Arizona; Oakland, California; Chicago, Illinois · 26 sites in all
- A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)Pivotal-lookingActive, not recruiting
Denali Therapeutics Inc.Industry
NCT05371613 · 65 participants · Start Jul 21, 2022 · Primary completion Dec 2027
Drug: tividenofusp alfa; idursulfase · For: Mucopolysaccharidosis II
Sites: Oakland, California; Chicago, Illinois; Hackensack, New Jersey · 30 sites in all
- Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive ImpairmentPivotal-lookingCompleted
ShireTakeda (TAK)
NCT02055118 · 58 participants · Start Mar 24, 2014 · Primary completion Sep 28, 2017
Drug: idursulfase-IT · For: Hunter Syndrome
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 9 sites in all
- Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT02412787 · 56 participants · Start Apr 14, 2015 · Primary completion Apr 18, 2024
Drug: Idursulfase-IT; Elaprase · For: Hunter Syndrome
Sites: Oakland, California; Chicago, Illinois; Chapel Hill, North Carolina · 9 sites in all
Green Cross CorporationIndustry
NCT01301898 · 31 participants · Start May 2010 · Primary completion Mar 2011
Drug: GC1111_0.5mg/kg; GC1111_1.0mg/kg and 1 more · For: Mucopolysaccharidosis II
Sites: Seoul, South Korea
- An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)Pivotal-lookingCompleted
GC Biopharma CorpIndustry
NCT07344376 · 30 participants · Start May 23, 2018 · Primary completion Dec 30, 2022
Drug: Hunterase · For: MPS II; Hunter Syndrome (MPS II); Hunter Syndrome and 2 more
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia618
- product dose omission issue495
- inappropriate schedule of product administration415
- infusion related reaction389
- cough312
- pneumonia300
- death271
- dyspnoea262
- influenza234
- seizure217
- covid-19207
- malaise199
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 10 |
| 2008 | 43 |
| 2009 | 96 |
| 2010 | 78 |
| 2011 | 73 |
| 2012 | 94 |
| 2013 | 230 |
| 2014 | 191 |
| 2015 | 281 |
| 2016 | 201 |
| 2017 | 189 |
| 2018 | 275 |
| 2019 | 253 |
| 2020 | 267 |
| 2021 | 661 |
| 2022 | 336 |
| 2023 | 284 |
| 2024 | 163 |
| 2025 | 137 |
| 2026 | 124 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elaprase (Idursulfase)
2024 spending
$7.0M
Beneficiaries
n/a
111 claims
Per beneficiary
n/a
$1,023.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,521,568 |
| 2021 | $6,158,923 |
| 2022 | $6,796,718 |
| 2023 | $6,048,528 |
| 2024 | $6,970,861 |
Part B: Elaprase (Idursulfase) · HCPCS J1743
2024 spending
$3.4M
Beneficiaries
n/a
163 claims
Per beneficiary
n/a
2024 ASP limit $542.16 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $952,367 |
| 2021 | $1,680,891 |
| 2022 | $1,800,137 |
| 2023 | $3,580,993 |
| 2024 | $3,382,670 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Phase 2/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II.
Okuyama T, Eto Y, Sakai N, et al. · Mol Ther 2021 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, et al. · Cochrane Database Syst Rev 2016 · Research Support, Non-U.S. Gov't, Systematic Review
- Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, et al. · Cochrane Database Syst Rev 2014 · Systematic Review
- Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, et al. · Cochrane Database Syst Rev 2011 · Systematic Review
- Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study.
Muenzer J, Burton BK, Harmatz P, et al. · Mol Genet Metab 2022 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Intravenous Idursulfase for the Treatment of Mucopolysaccharidosis Type II: A Systematic Literature Review.
Al-Hertani W, Pathak RR, Evuarherhe O, et al. · Int J Mol Sci 2024 · Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.